

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN 复星
復星國際有限公司
FOSUN INTERNATIONAL LIMITED
(Incorporated in Hong Kong with limited liability)
(Stock Code: 00656)

PROGRESS UPDATE
TERMINATION OF PUT OPTION

Reference is made to the joint announcement (the “**Announcement**”) of Fosun International Limited (the “**Company**”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) dated 27 October 2021, in relation to the acquisition and capital increase of Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.* (復星安特金(成都)生物製藥股份有限公司, the “**Target Company**”, formerly known as Chengdu Antejin Biotech Co., Ltd.* (成都安特金生物技術有限公司)) and issuing undertaking letters (the “**Undertaking Letters**”) to several shareholders of the Target Company to grant a put option by Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司, “**Fosun Pharma Industrial**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement. This announcement is made to provide further details in relation to the Put Option.

On 15 June 2026, Fosun Pharma Industrial and Put Option Holders entered into supplemental agreements to the Undertaking Letters (the “**Supplemental Agreements**”) to terminate the Put Option subject to an agreed automatic reinstatement clause, as detailed below:

In consideration of the Target Company’s current preparation for applying for listing on the Hong Kong Stock Exchange, and in support of the Target Company’s development, the Put Option Holders have irrevocably undertaken that the Put Option shall be automatically terminated upon the execution of the Supplemental Agreements and shall be automatically reinstated upon the *de facto* termination of the Target Company’s listing plan (including, but not limited to, the formal withdrawal or lapse of the listing application of the Target Company, or the occurrence of other circumstances that render the Target Company unsuitable for listing, if it occurs) (the “**Automatic Reinstatement Clause**”). The day immediately following the occurrence of any *de facto* termination event of the listing plan (whichever occurs earlier) under the Supplemental Agreements shall be the automatic reinstatement date (the “**Automatic Reinstatement Date**”).

The parties to the Supplemental Agreements agreed that, provided all research and development milestones stipulated in the Undertaking Letters are completed by 31 December 2026:

- (i) If the Put Option Holders regain the Put Option pursuant to the Supplemental Agreements, the latest exercise date of the Put Option shall be automatically extended to the Nth day after 31 December 2026 (where N equals the number of days from 1 January 2027 to the date on which any of the *de facto* termination event of the listing plan occurs). Simultaneously, Fosun Pharma Industrial agrees to compensate the Put Option Holders for the funding cost incurred during such N-day period, as follows:

Funding cost compensation for each Put Option Holder = Repurchase transfer price payable to such Put Option Holder (i.e., RMB93.83 × the amount of the registered capital or the corresponding number of shares of the Target Company subject to repurchase by Fosun Pharma Industrial as requested by such Put Option Holder) × then-current Loan Prime Rate (LPR) × N days;

- (ii) in any event, the validity period for exercising the Put Option reinstated under the Supplemental Agreements shall be no less than 90 calendar days from the Automatic Reinstatement Date; and
- (iii) the Automatic Reinstatement Clause shall terminate on the date the Target Company is successfully listed on the Hong Kong Stock Exchange.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

15 June 2026

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Huang Zhen and Mr. Pan Donghui; the non-executive directors are Mr. Li Fuhua and Mr. Luo Yuanli; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Dr. Lee Kai-Fu and Ms. Tsang King Suen Katherine.

**for identification purpose only.*